S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.00 (+0.53%)
F   12.14 (-0.90%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.07 (+0.30%)
DIS   107.67 (-1.62%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.85 (+2.04%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.00 (+0.53%)
F   12.14 (-0.90%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.07 (+0.30%)
DIS   107.67 (-1.62%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.85 (+2.04%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.00 (+0.53%)
F   12.14 (-0.90%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.07 (+0.30%)
DIS   107.67 (-1.62%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.85 (+2.04%)
S&P 500   4,981.80 (+0.13%)
DOW   38,612.24 (+0.13%)
QQQ   425.61 (-0.40%)
AAPL   182.32 (+0.42%)
MSFT   402.18 (-0.15%)
META   468.03 (-0.68%)
GOOGL   142.55 (+1.01%)
AMZN   168.59 (+0.90%)
TSLA   194.77 (+0.52%)
NVDA   674.72 (-2.85%)
NIO   5.97 (+0.17%)
AMD   164.29 (-0.84%)
BABA   75.58 (+3.34%)
T   17.00 (+0.53%)
F   12.14 (-0.90%)
MU   81.49 (+0.97%)
CGC   3.44 (-2.82%)
GE   149.07 (+0.30%)
DIS   107.67 (-1.62%)
AMC   4.57 (-1.93%)
PFE   27.67 (+0.29%)
PYPL   57.48 (-1.96%)
XOM   104.85 (+2.04%)

Cardiff Oncology (TROV) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

TROV vs. ACOR, PMCB, SNTI, AIM, BCLI, ZIVO, SRZN, IKT, EVAX, and COEP

Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Acorda Therapeutics (ACOR), PharmaCyte Biotech (PMCB), Senti Biosciences (SNTI), AIM ImmunoTech (AIM), Brainstorm Cell Therapeutics (BCLI), ZIVO Bioscience (ZIVO), Surrozen (SRZN), Inhibikase Therapeutics (IKT), Evaxion Biotech A/S (EVAX), and Coeptis Therapeutics (COEP). These companies are all part of the "medical" sector.

Cardiff Oncology vs.

Cardiff Oncology (NASDAQ:TROV) and Acorda Therapeutics (NASDAQ:ACOR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardiff Oncology
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Acorda Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Acorda Therapeutics received 60 more outperform votes than Cardiff Oncology when rated by MarketBeat users. However, 73.09% of users gave Cardiff Oncology an outperform vote while only 59.61% of users gave Acorda Therapeutics an outperform vote.

CompanyUnderperformOutperform
Cardiff OncologyOutperform Votes
402
73.09%
Underperform Votes
148
26.91%
Acorda TherapeuticsOutperform Votes
462
59.61%
Underperform Votes
313
40.39%

Acorda Therapeutics has a net margin of -14.35% compared to Cardiff Oncology's net margin of -3,688.31%. Acorda Therapeutics' return on equity of -21.45% beat Cardiff Oncology's return on equity.

Company Net Margins Return on Equity Return on Assets
Cardiff Oncology-3,688.31% -202.00% -122.92%
Acorda Therapeutics -14.35%-21.45%-4.25%

In the previous week, Acorda Therapeutics had 2 more articles in the media than Cardiff Oncology. MarketBeat recorded 2 mentions for Acorda Therapeutics and 0 mentions for Cardiff Oncology. Acorda Therapeutics' average media sentiment score of 0.13 beat Cardiff Oncology's score of 0.00 indicating that Acorda Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cardiff Oncology Neutral
Acorda Therapeutics Neutral

10.0% of Cardiff Oncology shares are owned by institutional investors. 0.6% of Cardiff Oncology shares are owned by insiders. Comparatively, 2.6% of Acorda Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Cardiff Oncology has higher earnings, but lower revenue than Acorda Therapeutics. Acorda Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiff Oncology$250K76.20-$16.41M-$2.80-0.62
Acorda Therapeutics$118.57M0.15-$65.92M-$17.11-0.81

Cardiff Oncology has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Acorda Therapeutics has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.

Summary

Acorda Therapeutics beats Cardiff Oncology on 9 of the 15 factors compared between the two stocks.


Get Cardiff Oncology News Delivered to You Automatically

Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TROV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TROV vs. The Competition

MetricCardiff OncologyBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ Exchange
Market Cap$19.05M$2.74B$4.93B$7.39B
Dividend YieldN/A2.40%2.91%3.85%
P/E Ratio-0.573.9794.1914.77
Price / Sales76.20282.273,006.64157.90
Price / CashN/A22.1681.8551.42
Price / Book1.843.744.224.62
Net Income-$16.41M$65.03M$111.40M$207.12M

Cardiff Oncology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ACOR
Acorda Therapeutics
0 of 5 stars
$15.20
+0.4%
N/A-23.9%$18.85M$118.57M-0.89111
PMCB
PharmaCyte Biotech
0 of 5 stars
$2.05
-5.5%
N/A-31.6%$17.67MN/A-3.472
SNTI
Senti Biosciences
2.1482 of 5 stars
$0.43
-2.3%
$4.00
+832.4%
-75.5%$19.11M$4.29M-0.27122Positive News
Gap Down
AIM
AIM ImmunoTech
0 of 5 stars
$0.40
-7.0%
N/A-18.4%$19.54M$140,000.00-0.9322
BCLI
Brainstorm Cell Therapeutics
3.7075 of 5 stars
$0.34
-5.6%
$10.00
+2,885.1%
-84.7%$16.41MN/A-0.7642Gap Down
ZIVO
ZIVO Bioscience
0 of 5 stars
$7.50
-11.8%
N/A-57.2%$20.70MN/A0.008Gap Down
SRZN
Surrozen
0 of 5 stars
$10.40
+13.7%
N/A+0.3%$21.22M$12.50M-0.6074Gap Down
High Trading Volume
IKT
Inhibikase Therapeutics
3.0195 of 5 stars
$2.47
-3.5%
$27.00
+993.1%
-50.0%$15.24M$120,000.00-0.636Positive News
Gap Down
EVAX
Evaxion Biotech A/S
2.8182 of 5 stars
$4.00
-5.0%
$42.00
+950.0%
-74.6%$15.16MN/A-0.4263Positive News
COEP
Coeptis Therapeutics
2.6468 of 5 stars
$0.42
-6.6%
$4.33
+924.4%
-63.4%$14.43M$80,000.000.004Upcoming Earnings
Gap Up

Related Companies and Tools

This page (NASDAQ:TROV) was last updated on 2/21/2024 by MarketBeat.com Staff